Editas Medicine (NASDAQ:EDIT) 报告季度每股亏损$0.55，低于分析师普遍预期的$0.38，相差44.74%。与去年同期每股亏损$0.23相比，这是一个139.13%的下降。公司报告季度销售额为$30.604百万，低于分析师普遍预期的$32.230百万，相差5.04%。与去年同期的$60.050百万相比，这是一个49.04%的下降。
以上内容来自Benzinga Earnings专栏，原文如下：
Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.38) by 44.74 percent. This is a 139.13 percent decrease over losses of $(0.23) per share from the same period last year. The company reported quarterly sales of $30.604 million which missed the analyst consensus estimate of $32.230 million by 5.04 percent. This is a 49.04 percent decrease over sales of $60.050 million the same period last year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.